Novo Nordisk Launches Ozempic in India
Novo Nordisk has introduced Ozempic, an injectable semaglutide treatment for type 2 diabetes, to the Indian market. This positions the drug as a significant addition to their diabetes care offerings, complementing Wegovy, their recently launched obesity medication.
Vikrant Shrotriya, Managing Director of Novo Nordisk India, stated that Ozempic is being offered in three dosage strengths: 0.25 mg, 0.5 mg, and 1 mg. These dosages are specifically for patients diagnosed with type 2 diabetes. It was clarified that the 2.4 mg dose of semaglutide, already available in India, remains exclusively for obesity treatment under the Wegovy brand.
Patient Preferences and Treatment Options
Shrotriya explained that the company's decision to expand its injectable portfolio, despite the availability of oral semaglutide Rybelsus, reflects evolving patient preferences. According to Shrotriya, there's increasing patient acceptance of injectable treatments, a trend not previously observed even with insulin. Rybelsus, however, continues to exhibit growth.
He also noted that approximately 75% of diabetes patients in India still prefer oral medication. This underscores the need for a versatile treatment portfolio that accommodates both injectable and oral options. Health tracking apps like Shotlee can help monitor medication adherence and blood sugar levels.
Precision tracking for your journey
Join thousands using Shotlee to accurately track GLP-1 medications and side effects.
📱 Get the Shotlee App
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
Pricing and Market Competition
Regarding pricing, Shrotriya indicated that Ozempic would be priced similarly to Wegovy. This follows Novo Nordisk's recent decision to reduce Wegovy prices in India by nearly 37% to enhance affordability. The company believes this price point will allow more patients to access injectable semaglutide, making alignment between the two products important.
Addressing concerns about the semaglutide patent expiring in March 2026, Shrotriya suggested that increased competition could raise awareness and boost overall treatment adoption. He stated that Novo Nordisk welcomes competition, provided it demonstrates a long-term commitment to patient care.
Given that diabetes affects over 100 million individuals in India, the introduction of Ozempic marks another advancement in broadening treatment options for a condition that places a substantial burden on the country's healthcare system.
